In the IDEAL trial, 1824 postmenopausal hormone receptor-positive breast cancer patients were randomly assigned, after 5 years of any endocrine adjuvant therapy, to groups receiving either 2.5 or 5 years of letrozole. This evidence concerns the gene NR4A1 and breast cancer.